Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
Recruiting
Phase 2
Phase 3
Interventional Study
Recurrent Ovarian Cancer
Signal Transduction Pathway Deregulation
Therapy-Associated Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 148 (estimated)
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel mRNA-based assay. Existing targeted drugs with tolerable toxicity profiles are used to investigate the therapeutic value beyond their approved indication, which are deemed be…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female, age \> 18 years
* Patients with recurrent ovarian cancer who meet one of the following criteria:
* Platinum-resistant disease, defined as disease recurrence or progression within six months of last platinum-based chemotherapy or;
* Patient refrains from standard therap…
Contacts